SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation - Additional Information (Details) - USD ($)							12 Months Ended
	Dec. 13, 2021	Jul. 29, 2021	Mar. 31, 2021	Feb. 17, 2021	Feb. 14, 2020	Oct. 25, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Cash							$ 743,000,000	$ 709,000,000	$ 696,000,000
Total cash consideration, net of cash acquired							10,502,000,000	$ 494,000,000	$ 418,000,000
Cheetah Medical, Inc.
Summary Of Significant Accounting Policies [Line Items]
Consideration transferred						$ 208,000,000
Cash consideration transferred						190,000,000
Total assets acquired						$ 208,000,000
Percentage of ownership acquired						100.00%
Total cash consideration, net of cash acquired						$ 188,000,000
Consideration transferred, additional potential amounts						40,000,000
Contingent Consideration						$ 18,000,000
Hillrom
Summary Of Significant Accounting Policies [Line Items]
Purchase price	$ 10,500,000,000
Enterprise value	12,800,000,000
Consideration transferred	10,476,000,000
Cash consideration transferred	10,474,000,000
Total assets acquired	$ 10,476,000,000
Total assets acquired							$ 142,000,000
Seprafilm Adhesion Barrier
Summary Of Significant Accounting Policies [Line Items]
Cash consideration transferred					$ 342,000,000
Total assets acquired					342,000,000
PerClot
Summary Of Significant Accounting Policies [Line Items]
Cash		$ 25,000,000
Contingent consideration liability		36,000,000
Total assets acquired		53,000,000
Contingent Consideration		$ 28,000,000
Transderm Scop
Summary Of Significant Accounting Policies [Line Items]
Cash			$ 60,000,000
Contingent consideration liability			30,000,000
Total assets acquired					$ 84,000,000
Contingent Consideration			$ 24,000,000
Caelyx and Doxil
Summary Of Significant Accounting Policies [Line Items]
Cash consideration transferred				$ 325,000,000